

Adaptimmune Therapeutics PLC  
Form 8-K  
July 03, 2017

**UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION**

Washington, D.C. 20549

**FORM 8-K**

**Current Report**

**Pursuant to Section 13 or 15(d) of  
the Securities Exchange Act of 1934**

Date of Report (Date of earliest event reported): **July 1, 2017**

**ADAPTIMMUNE THERAPEUTICS PLC**

(Exact name of registrant as specified in its charter)

**England and Wales**  
(State or other jurisdiction of incorporation)

**1-37368**  
(Commission File Number)

**Not Applicable**  
(IRS Employer Identification No.)

**101 Park Drive, Milton Park  
Abingdon, Oxfordshire OX14 4RY**

**United Kingdom**

(Address of principal executive offices, including zip code)

**(44) 1235 430000**

Edgar Filing: Adaptimmune Therapeutics PLC - Form 8-K

(Registrant's telephone number, including area code)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

**Item 8.01 Other Events.**

Effective July 1, 2017, Adaptimmune Therapeutics plc (the Company or Adaptimmune), assigned to Immunocore Limited ( Immunocore ) all of the Company's rights, interests, obligations and responsibilities under a lease, dated as of June 24, 2015, between MEPC Milton Park No. 1 Limited and MEPC Milton Park No. 2 Limited (the Landlord ) and the Company with respect to approximately 9,695 square feet of office space at Building 101, Milton Park, Oxfordshire, U.K. (the Lease Assignment ). The Landlord consented to the Lease Assignment on June 30, 2017.

The Lease Assignment followed the relocation of the Company's staff into the Company's new 67,140 square foot building at Milton Park, Oxfordshire ( Building 60 ) in June 2017. Building 60 comprises laboratory and office space and accommodates all of the Company's U.K. operations.

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned, hereunto duly authorized.

ADAPT IMMUNE THERAPEUTICS PLC

Date: July 3, 2017

By: /s/ Margaret Henry  
Name: Margaret Henry  
Title: Corporate Secretary